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Abstract 
 
Ufd2a is an E3 enzyme that adds ubiquitin to proteins that will then be sent to a 
proteosome to be degraded. Previous experiments have shown an interaction between 
Ufd2aI (in yeast and mouse) and the ubiquitous AAATPase, p97/VCP, which binds to 
ubiquitylated proteins and has many essential functions in the cell which range from 
mitosis to autophagy. Mutations in the p97/VCP gene resulting in amino acid 
substitutions R155H or A232E are present in cases of Paget’s disease of the Bone with 
Frontotemporal Dementia (IBMPFD), a type of inclusion body myopathy which presents 
with an accumulation of autophagosomes. Using quantitative reporter systems we 
developed for the Yeast 2-Hybrid assay we have found that Ufd2aI has the strongest 
affinity for p97/VCP A232E, while its weakest interaction is with wild type p97/VCP. 
Since p97/VCP is known to bind to a number of diverse molecules in a mutually 
exclusive manner, we speculate that a stronger interaction between Ufd2aI and mutant 
p97/VCP may inhibit other interactions essential to its function in resolving ubiquitylated 
protein loaded autophagosomes.  
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Introduction 
 
Ufd2a Isoforms 
Ufd2a is a protein that is part of the ubiquitin-proteosome pathway. It is an E3 
enzyme that adds ubiquitin to proteins that will then be sent to a proteosome to be 
degraded (Kogel 199, Kaneko 29003, Mahoney 2002,). There are three different splice 
forms of Ufd2a that are found only in muscle cells. Ufd2a is the shortest isoform of the 
protein and it includes exons one though six and eight through twenty-seven.  It is 
expressed in most dividing cells of mammals and in precursor muscle cells called 
myoblasts. Ufd2aII is the second largest isoform which consists of exons one through six, 
seven, and eight through twenty-seven. This form of Ufd2a appears to be exclusively 
expressed during the differentiation of myoblast cells. The third form, Ufd2aIII, consists 
of all exons contained in Ufd2aII as well as the newly discovered exon 7a. This form of 
the protein is only expressed in later stages of muscle differentiation and in mature, 
striated, multinucleated muscle cells.  
 
Yeast 2 Hybrid System 
The identification of novel protein-protein interactions (PPIs) can help to discover 
proteins that are part of the same cellular pathway. For example if one protein is known 
to play a role in the regulation of cell division, and a second protein was discovered to 
interact with it, then it could be hypothesized that the two are involved in the same 
process. Therefore, when a novel interaction is found, new hypotheses can be generated 
about the function of interacting protein pair.  The Yeast 2 Hybrid (Y2H) is one method 
by which to identify novel interactions between proteins in cells. This technique was 
developed using the knowledge of the yeast Gal4 transcription factor and promoter 
region. It was discovered that the DNA-binding domain and the activation domain of the 
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Gal4 transcription factor could be expressed as two separate proteins and still induce 
transcription of any gene placed downstream of the Gal4 promoter as long as the two 
domains were brought into close proximity. Therefore, when one protein, referred to as 
the bait, is fused to the DNA-binding domain and a second, referred to as the prey, is 
fused to the activation domain, transcription of the gene downstream of the Gal4 
promoter will occur if the bait and prey interact. 
In a version of the Y2H system developed by Invitrogen, there are two pDEST 
vectors that the bait and prey genes of interest are inserted into. They either contain the 
DNA Binding Domain (DBD; pDEST32) or the Activation Domain (AD; pDEST22) of 
the Gal4 transcription factor coded for upstream of where the genes of interest are 
inserted, such that the final proteins will be fusion products. 
These two vectors are first made in bacteria, they each also encode an antibiotic 
resistance gene so that when in bacteria they are able to be selected for using that 
antibiotic resistance gene. Once the vectors have been authenticated (by sequencing), 
they are transformed into yeast where the two fusion proteins will be expressed. The 
vectors also contain either a leucine synthase gene or a tryptophan synthase gene which 
allow for selection of yeast that have both vectors when grown on plates lacking these 
two amino acids.   
 
Reporter System of Yeast 2 Hybrid System  
The particular strain of yeast used in this Y2H system, MaV203 has been 
engineered such that several reporter genes which include the histidine synthase HIS3 and 
lacZ gene, are placed downstream of a Gal4 promoter; this allows an interaction to be 
detected depending on either the type of media the yeast are grown on or through a  
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β-galactosidase assay performed on the yeast cells.   
Detection of transcription of the histidine synthase is through growth on a –his/– 
leu/–trp plate containing different concentrations of 3-amino-1,2,4-triazole (3AT) which 
is a histidine antagonist. The stronger the interaction of the bait and prey, the more 
histindine synthase produced by the yeast, allowing them to survive on higher 
concentrations of 3AT. This gives you a qualitative estimate of the strength of the 
interaction. Detection of transcription of the lacZ gene is done by incubating the cells 
with a substrate which forms a blue precipitate inside the yeast cells when cleaved by β-
galactosidase, the enzyme product of the LacZ gene. The rate and intensity of color 
development provide an estimate of the strength of the interaction. Combining the results 
from these two assay systems allows verification of the interaction and eliminates false 
positives. 
 
VCP/p97 and Inclusion Body Myopathy associated with Paget’s disease of the Bone 
and Frontotemperal Dementia (IBMPFD) 
Previous experiments have shown that there is an interaction between Ufd2aI (in 
yeast and mouse) and VCP/p97. It is part of the AAAtpase family of proteins.VCP/p97 
binds to ubiquitilated proteins and has many essential functions which range from mitosis 
to autophagy. Mutations in the p97/VCP gene resulting in amino acid substitutions 
R155H or A232E are present in cases of Paget’s disease of the Bone with Frontotemporal 
Dementia (IBMPFD), a type of inclusion body myopathy which presents with an 
accumulation of autophagosomes (Ju and Weihl, 2010). There is some evidence that the 
VCP/p97 R155H and VCP/p97 A232E interact with Ufd2aI (UI) in mouse and human 
cells (Paul Taylor, personal communication).  
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Through histidine synthase assays and β-Galactosidase assays in the Yeast 2 
Hybrid system it was found there was no binding between Ufd2aIII and VCP/p97. 
However there was significant binding between Ufd2a and VCP/p97. This led us to 
question whether the binding affinity for mutations in VCP/p97 that is involved in the 
autosomal dominant disease Inclusion Body Myopathy in association with Paget’s 
disease of the Bone and Frontotemperal Dementia. It was found that there was a 
significant difference in the binding between VCP/p97 Wild Type, R155H, and A232E.  
 
Materials and Methods: 
 
Cloning of Ufd2a and Ufd2aIII, VCP/p97 (WT, R155H, and A232E) 
 
LR Clonase II Reaction 
The Invitrogen Gateway system was used to clone Ufd2a into a p-DEST vector. 
The Invitrogen system takes a plasmid that is specially modified for use in the Yeast 2 
Hybrid system (Y2H). The plasmid has a ccdB death gene in between att sites. The 
purpose of this system allows you to easily switch out the death gene with Ufd2a by a LR 
Clonase II reaction. 150 ng of the entry clone (Ufd2a) which is in an entry vector 
pDONR (from Bio 533 Spring 2010) which must be between 1-7 µl, 150 ng of 
destination vector  pDEST32 for Ufd2a and Ufd2aIII and pDest22 for VCP/p97 and 
mutants, add TE Buffer until 8 µl pH 8.0 was added to a 1.5 ml microcentrifuge tube. The 
LR clonase mixture was thawed on ice for two minutes and mix by shaking for 
approximately 2 seconds, twice. To each sample add 2 µl of LR clonase mixture. This  
was then mixed briefly. The reaction was incubated at 25oC for 1 hour. 1 µl of proteinase 
K solution was added to complete reaction. Mix briefly again. This mixture was then 
incubate at 37oC for ten minutes. 
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Heat Shock Transformation 
 40 µl of DH5α max cells (E. coli) (Invitrogen) were thawed  on ice in a 1.5 ml 
microcentrifuge tube. 1 µl of LR reaction was pipietted into tube of cells and waited 15 
minutes. Cells were placed in a 42oC water bath for 45 seconds. Immediately the tube 
was placed on ice for 2 minutes. 100 µl of SoC media was added and flick tube to mix. 
Tube was placed in shaker (approximately 200rpm) for 1 hour at 37oC. Tube was 
removed from shaker and entire contents were spread on LB-antibiotic plate (gentamicin 
for pDEST32 and ampicillin for pDEST22) and incubated overnight at 37oC.  
 
Liquid Cultures for Miniprep Kit 
3 ml of sterile Luria broth (LB) media was added to a 15 ml test tube. Gentamicin 
or ampicillin was added to media depending which vector being used ( 5000x stock of 
gentamicin is 50 mg/ml, so to a 3 ml culture 0.6 µl of gen is added, 1000x stock of 
ampicillin is 30 mg/ml so 3 µl is added to a 3 ml culture). With a sterile pipette tip, touch 
a colony and place the tip into a tube. Tube was placed in shaker overnight at 37oC 
 
Miniprep Kit 
Using the Bench Protocol of the QIAprep Spin Miniprep Kit, samples were 
centrifuged in a 1.5 ml microcentrifuge tube. Use all 3 ml, this will have to be divided 
into two 1.5 ml aliquots. Use same tube a second time. The pellet was resuspended in 250 
µl of Buffer P1. 250 µl of Buffer P2 was added and mixed by inversion. Solution should 
turn blue (if using LyseBlue). 350 µl of Buffer N3 was added and mixed by inversion. 
Solution should turn colorless (if using LyseBlue). Solution was centrifuged for 10 
minutes at 13000 rpm. The supernatant was applied to QIAprep spin column by pipetting. 
Spin column was centrifuged for 60 seconds. Flow through was discarded. 500 µl Buffer 
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PB was added to wash the column. Again the column was centrifuged for 60 seconds. 
Flow through was discarded. The spin column was washed again with 750 µl Buffer PE. 
Column was centrifuged for 60 seconds. Flow through was discarded and spun again for 
60 seconds. Spin column was placed in a clean 1.5 ml microcentrifuge tube and  50 µl 
Buffer EB was added to elute the protein, elution buffer was allowed to sit 60 seconds 
and centrifuged for 1 minute. Determined the concentration of the sample using a 
Nanodrop spectrophotometer.  
 
Restriction Digest (using PvuII) 
 Restriction digests were performed to ensure the proper sequence of the Ufd2a 
(VCP/p97 and mutants were in destination vectors and verified as the proper sequences, 
Bio 533 spring 2010 class). 2 µl of Buffer 2 (10x stock), 1 µl PvuII enzyme (both from 
NE biolabs), 250-500 ng of DNA (can be less if concentration is low), and dH2O until 20 
µl was added to microcentrifuge tube. Mixture was incubated at 37oC for 2 hours. Tubes 
were taken out of incubation, 4 µl 6x DNA was added. Prepare a 0.8% agarose gel adding 
ethidium bromide. Samples were added to wells (include 1kb+ ladder). Run gel at 100 
volts for 25-35 minutes. Gel was then visualized with UV light. The expected band 
patters should be at 927, 1092, 1689, 4120, and 6151 base pairs.  
 
Restriction Digest (using BamHI and NcoI) 
 Used same protocol as above except use Buffer 3 (NE biolabs) and 0.5 µl of each 
restriction enzyme. The expected band pattern is 1423, 4614, and 7942 base pairs.  
 
 
Site Directed  Mutagenesis of Ufd2aIII  
Using the LR Clonase II reaction did not work with Ufd2aIII. Therefore site directed 
mutagenesis was used instead. Ufd2aIII was in a different vector (pDEST201; obtained 
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from Brenda Cordiero). This vector did not have a stop codon and when put into the 
pDEST32 vector it would not be in the correct reading frame. Therefore to correct that 
problem site directed mutagenesis used.  Using the QuikChange Lightning Enzyme 
(Agilent) for Mutant Strand Synthesis Reaction prepared in a PCR tube 5 µl 10x reaction 
buffer, 25 ng of DNA, 125g ng stop codon primer forward, 125 ng stop codon primer 
reverse, 1 µl dNTP mix, 1.5 µl QuikSolution reagent, dH2O to a final volume of 50 µl.    
1 µl QuikChange Lightning Enzyme was then added and put into PCR machine. Follow 
chart temperatures and times. When stop codon was added there was a particular 
restriction enzyme that cleaved the stop codon site (BfaI) using this enzyme as previously 
stated in restriction enzyme section using 1 µl of BfaI and Buffer 4 (NE biolabs) the 
sequence was confirmed by the banding pattern. Using the same protocol with different 
primers (these primers added a nucleotide to shift the reading frame) the procedure was 
carried out a second time. There was no convenient enzyme that would cleave the new 
frame shift so the reaction was sent to the Genome Sequencing Center at The University 
of Rhode Island.  
 
Segment Cycles Temperature Time 
1 1 95oC 2 min 
2 18 
95oC 20 sec 
60oC 10 sec 
68oC 
30 
sec/kb  
plasmid 
length 
3 1 68oC 5 min 
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Sequencing of Ufd2a, Ufd2aIII, VCP/p97 and Mutants 
 Colonies that had the correct banding pattern with the restriction enzymes were 
sent to the Genome Sequencing Center at the University of Rhode Island to confirm the 
correct sequence of each protein.  
 
Transformation into Yeast Cells 
 
Preparation of Competent Cells 
 The S.c EasyComp Transformation Kit (Invitrogen) was used when 10 ml of YPD 
media was inoculated with singe colony of S. cerevisiae strain (Mav203) overnight at 
30oC in a shaking incubator (200-350 rpm). OD600 of overnight culture was determined, 
which should be between 3.0 and 5.0. Cells were then diluted to an OD600 of 0.2 – 0.4 in 
a total volume of 10 ml of YPD. Grow cells in shaking incubator until OD600 0.6 – 1.0, 
this should take between 3 and 6 hours.  Cells were centrifuged at room temperature for 5 
minutes and 500 rpm, supernatant was discarded. Resuspend pellet in 10 ml of solution 1. 
Cells were centrifuged at room temperature for 5 minutes and 500 rpm, the supernatant 
was discarded. Celled were resuspended  in 1 ml of solution 2. Cells were competent and 
could be used immediately or frozen in 50 µl aliquots.  
 
Transformation of Competent Cells  
 For each transformation one aliquot of 50 µl of competent cells was thawed. 1 µg 
of vector DNA Ufd2a and VCP/p97 (see graph) (no more then 5 µl each) to competent 
cells was added to aliquot. 500 µl of Solution 3 (Invitrogen S.c. EasyComp 
Transformation Kit) was then added to each tube and mixed. Reaction was incubated  at 
30oC for 1 hour. Every 15 minutes aliquots were shaken to mix contents for superior 
transformation efficiency. 150 µl of reaction was plated on -leu/-trp deficient 1.5% agar 
plates. 
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Bait Vector Prey Vector 
pDEST32-
Ufd2a empty pDEST22 
pDEST32-
Ufd2aIII empty pDEST23 
pDEST32-
Ufd2a pDEST22-VCP WT 
pDEST32-
Ufd2a 
pDEST22-VCP 
R155H 
pDEST32-
Ufd2a 
pDEST22-VCP 
A232E 
empty 
pDEST32 pDEST22-VCP WT 
empty 
pDEST33 
pDEST22-VCP 
R155H 
empty 
pDEST34 
pDEST22-VCP 
A232E 
 
 
Histidine Synthase Growth Assays 
Liquid Growth Assay 
4 ml of –leu/-trp/-his liquid sterile media was added to a 15 ml conical tube. With a 
sterile pipette tip, touch a colony and place the tip into a tube. Tube was placed in shaker 
overnight at 30oC to an OD600 of between 2.0 and 3.0. Culture was diluted down to OD600 
of 1.0. In a five 96-well plate serial dilutions of  in a 1:5, 1:50, 1:500, 1:5000, 1:50000 
ratio in –leu/-trp media 10 mM 3-amino- 1,2,4-triazole (3AT) sterile liquid media, 25 
mM 3AT liquid sterile media, 50 mM 3AT liquid sterile media, 100 mM 3AT liquid 
sterile media in triplicates. This is a quantitative assay that can be read with an ELISA 
reader at 600 nm.  
 
Plate Growth Assay 
4 ml of –leu/-trp/-his liquid sterile media was added to a 15 ml conical tube. Touch the tip 
of sterile pipette into yeast colony. Place into conical tube. Grow overnight at 30oC to an 
OD600 of between 2.0 and 3.0. Culture was diluted to an OD600 of 1.0. In a 96-well plate 
the cultures were serial diluted in a 1:5, 1:50, 1:500, 1:5000, 1:50000 ratio of culture to 
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media. Using a frogger replicate the 96-well plate onto a –leu/-trp plate (control plate), 10 
mM 3AT, 25 mM (3AT),   50 mM 3AT, and 100 mM 3AT. Plates were incubated for 2-4 
days.  
 
Liquid β-Galactosidase Assay 
4 ml of –leu/-trp media was added to 15 ml conical tubes and shaken at 30oC overnight at 
200 rpm. Take the OD600. The culture was diluted to an OD600 of 0.3 in 4 ml of fresh       
–leu/-trp media and shook at 30oC until OD600 of 1.0-1.5 (this should take approximately 
4.0-4.5 hours). Aliquots were centrifuged,  3 ml of culture in 1.5 ml microcentrifuge tube 
(12000 x g) for 30 seconds and the supernatant was discarded. 500 µl Z Buffer was added 
to wash cells. Cells were resuspended in 300 µl of Z Buffer and then disrupted by adding 
0.150 g of acid washed glass beads and mixing with a Vortex mixer for 30-45 minutes. 
Beads settled to the bottom of the tube and liquid fraction was pipetted off and added to 
350 µl Z Buffer, 0.9 µl of β-2-mercaptoethanol, 80 µl of 4mg/ml ONPG in Z Buffer. 
Reaction was incubated at 30oC for 14 hours and 15 minutes. Reactions were stopped by 
the addition of 400 µl of Na2CO3. Tubed were centrifuged at 12000 x g for 5 minutes. 
Supernatants were collected and pipetted 200 µl into a 96-well plate in triplicates. Plate 
was read at 420 nm. The β-Galactosidase activity is calculated by the equation 1000 x 
A420 nm / (t x V x A600 nm). Where t = time and  v = volume of culture in ml.   
Chapter I: UFD2a vs UFD2a III interaction with VCP/p97 
Introduction: 
 Ufd2a has three different isoforms in muscle cells. There is a different isoform 
present in the cells depending on the stage of development. In myoblasts or precursor 
muscle cells Ufd2a is present. It is the shortest isoform containing exons one through six 
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and eight through twenty-
seven. The second isoform, 
Ufd2aII is present in 
differentiated muscle cells 
that have not begun to fuse 
together. This isoform had 
exons one through seven and 
eight through twenty-seven. 
The third isoform is found in multinucleated, striated muscle cells. It includes exons one 
through seven, seven ‘a’, and eight through twenty-seven. There have been implications 
through other research that Ufd2a interacts with VCP/p97 (Paul Taylor personal 
communication). However, there is no information as to the binding of VCP/p97 to either 
of the other isoforms. This experiment looks at the binding affinities of Udf2a and 
Ufd2aIII with VCP/p97.  
 
Results: 
The Yeast 2 Hybrid (Y2H) system works with the Gal4 promoter. The Gal4 
promoter has a DNA binding domain (DBD) and an activation domain (AD) that in a 
Wild Type promoter facilitates the transcription of the gene downstream from the 
promoter. It was found that the binding domain and activation domain could be 
separated. The DBD and AD are then fused to potential proteins that may interact with 
each other. If the two proteins interact with each other, the DBD and AD are now in 
proximity to each other and can drive the transcription of the reporter system.  
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The vectors used for the Y2H system are pDEST32 and pDEST22 (Invitrogen). 
These two vectors are built specifically for the Y2H system. These vectors are 
transformed into E. coli cells and Mav203 yeast cells. To be able to select colonies in     
E. coli there are antibiotic resistance genes gentamicin and ampicillin respectively. To 
select colonies in yeast the two vectors together have tryptophan synthase (trp 1) and 
leucine synthase (leu 2). The two vectors are transformed yeast cells and they are then 
selected for on –leu/-trp deficiency media. The cells that have both vectors are then 
subjected to a multitude of tests to observe if an interaction is present.  
 
Histidine Synthase Assays 
 There are two histidine synthase reactions. The plate assay is a qualitative assay 
that generates a visual result. The plates can then be viewed and a general idea of the 
strength of reaction between the two proteins can be observed. The histidine synthase 
reaction works with an antagonist, 3-amino-1, 2, 4-triazole (3AT). 3AT impairs the 
production of histidine. When placed on an agar plate that has –leu/-trp/-his deficiency 
media and a molar quantity of 3AT either 10 mM, 25 mM, 50 mM, or 100 mM the 
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gradient of 3AT impedes the synthesis of histidine in a concentration-dependent manner. 
If a bait and prey protein pair 
grows on the higher concentrations 
then it can be said to have a strong 
binding affinity. If the protein pair 
only grows on the lower 
concentrations then it can be said 
to have a weaker binding affinity.  
Figure 3 shows Ufd2a binding with VCP/p97 in such an assay, however in the same 
assay Ufd2aIII does not bind with VCP/p97. Figure 4 shows a quantitative histidine 
synthase liquid assay where  significant binding occurs between Ufd2a and VCP/p97 (p = 
0.008). The binding of Ufd2aIII and VCP/p97 corroborates the liquid assay in that 
Ufd2aIII does not bind to VCP/p97.  
 
 
 
 
 
 
 
β-Galactisodase Liquid Assay 
The liquid β-Galactisodase assay is a liquid color changing assay. The aqueous 
solution changes from a clear color to a distinct bright yellow color when the                  
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β-Galactosidase cleaves its 
substrate. The variation in 
color allows the assay to be a 
quantitative assay read at 420 
nm. The equation            
(1000xA420)/ (t x V x A600) 
allows the assay to give a β-
Galactisodase unit which shows the activity of the binding proteins (where t is time and v 
is volume of culture). This assay also corroborates both histidine synthase assays in that 
there was no binding between Ufd2aIII and VCP/p97 but there was significant binding 
between Ufd2a and VCP/ p97.  
Conclusions: 
 The histidine synthase asssays along with the β-Galactisodase assay yielded 
consistent results with regard to the binding affinity of Ufd2aIII and VCP/p97. There was 
no significant binding between the two proteins in either of the assays.  Converesely, 
Ufd2a and VCP/p97 do have a significant binding affinity. This observation leads to the 
next question: is the binding affinity of Ufd2a affected by mutations in VCP/p97.  
 
Chapter 2: UFD2a interaction with VCP/p97 mutants 
Introduction:  
Inclusion body myopathy in association with Paget’s disease of the bone and 
frontotemperal dementia (IBMPFD) is a progressive, autosomal dominant disorder that is 
caused by mutations in VCP/p97 including R155H and A232E. Particular mutations in 
VCP/p97 such as A232E can exhibit a stronger phenotypic expression of IBMPFD. 
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These mutations occur in the C-domain of VCP/p97 as seen in the blue central unit in 
figure 6 (Ju and Weihl, 2010). 
R155H and A232E are two point 
mutations that change one animo 
acid in the protein. R155H is 
originally an arginine that 
changes to a histidine at amino 
acid number 155. Similarly, 
A232E was originally an alanine 
which changed to a glutamic acid 
at amino acid number 232.  
Results:  
Histidine Synthase Assays 
The histidine synthase plate assay was employed to visualize if there a stronger binding 
affinity for VCP/p97 Wild Type or if Ufd2a bound stronger to one of the mutant forms 
(R155H or A232E) used in these experiments. In this assay it appears that there was 
binding between Ufd2a and all three VCP/p97 forms, but that the strength of binding 
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differed between the three forms of VCP/p97. VCP/p97 A232E had the strongest binding 
affinity for Ufd2a. The next strongest binding affinity was with VCP/p97 R155H and the 
weakest affinity was with VCP/p97 Wild Type (Figure 7). The liquid histidine synthase 
assay corroborates the plate assay with a p < 0.001 (Figure 8).  
 
 
 
 
 
 
 
 
 
 
 
 
                
 
β-Galactosidase Assay  
The β-Galactosidase assay is not as sensitive as the histidine synthase assay. It can only 
be used to determine if 
there is a strong reaction. 
The assay showed that 
there was a significant 
binding affinity between 
Ufd2a and VCP/p97 
A232E. There was no 
significant binding in this 
assay between the other two forms of VCP/p97 (Wild Type or R155H) the p < 0.001.   
 
 22
 
Conclusions: 
In this set of assays it is clear that there are differences in the binding affinities of 
Ufd2a and the three forms of VCP/p97. The histidine synthase assays show that there are 
differences between the three different forms of VCP/p97 and the control groups but that 
there is also a difference in the binding affinities of VCP/p97 Wild Type, R155H, and 
A232E. With the corroboration of the B-Galactosidase assay it is clear that VCP/p97 
A232E has the strongest binding affinity.  
 
Overall Conclusions: 
Consistent results showed that there was not binding between Ufd2aIII and 
VCP/p97. How ever there was significant binding between Ufd2a and VCP/p97. This 
significance was thought to occur when the experiment began and this confirmed the 
suspicion that these two proteins interacted with each other in the proteosome pathway. 
When looking at the comparison of Ufd2a and VCP/p97 Wild Type, R155H, and A232E 
there was a significant difference in the binding affinities not just between the controls 
and the three forms of VCP/p97 individually.  
 
Discussion: 
Ufd2a has a multitude of functions. It adds ubuquitin to specific substrates, it adds 
chains of ubiquitin to specific substrates, it works in the proteosome degradation 
pathway, it may work with autophagy, and it also binds to VCP/p97 where it affects the 
disease inclusion body myopathy in association of Paget’s disease of the bone and 
frontotemperal dementia.  
Ufd2aIII does not bind to VCP/p97. This is thought to be an exclusive binding 
partner. Therefore in mature, multinucleated, striated muscle cells VCP/p97 is able to 
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bind to other cofactors. The binding of VCP/p97 to these other cofactors might be what 
are affecting the people that have IBMPFD.  
Ufd2a had a strong binding affinity for VCP/p97 A232E and R155H. These 
specific mutations give a stronger phenotypic manifestation of the disease and now it can 
be linked to a stronger binding affinity to Udf2a. Perhaps the reason for this stronger 
phenotypic manifestation is because Ufd2a is binding so tightly that it is not releasing 
VCP/p97 so that it can work with its other binding partners. It has been determined that a 
deficiency of VCP/p97 by knockdown or over expression of dominant negative VCP/p97 
results in a significant accumulation of immature autophagic vesicles; some are 
abnormally large, others acidified and exhibit cathepsin B activity. However, the disease 
mutants R155H and A232E also cause this defect in autophagic vesicles (Tresse and 
Taylor et al, 2010). These autophagic vesicles are part of the IBMPFD disease.  
Further research will be conducted to see if Ufd2aIII has a significant binding 
affinity for any of the VCP/p97 mutants.   
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